1. Mann, M. & Jensen, O. N. (2003) Proteomic analysis of post-translational modifications, Nat Biotechnol. 21, 255-61.
2. Aebersold, R. & Mann, M. (2016) Mass-spectrometric exploration of proteome structure and function, Nature. 537, 347-55.
3. Hsu, P. P., Kang, S. A., Rameseder, J., Zhang, Y., Ottina, K. A., Lim, D., Peterson, T. R., Choi, Y., Gray, N. S., Yaffe, M. B., Marto, J. A. & Sabatini, D. M. (2011) The mTOR- regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling, Science. 332, 1317-22.
4. Huttlin, E. L., Jedrychowski, M. P., Elias, J. E., Goswami, T., Rad, R., Beausoleil, S. A., Villen, J., Haas, W., Sowa, M. E. & Gygi, S. P. (2010) A tissue-specific atlas of mouse protein phosphorylation and expression, Cell. 143, 1174-89.
5. Olsen, J. V., Blagoev, B., Gnad, F., Macek, B., Kumar, C., Mortensen, P. & Mann, M. (2006) Global, in vivo, and site-specific phosphorylation dynamics in signaling networks, Cell. 127, 635-48.
6. Francavilla, C., Rigbolt, K. T., Emdal, K. B., Carraro, G., Vernet, E., Bekker-Jensen, D. B., Streicher, W., Wikstrom, M., Sundstrom, M., Bellusci, S., Cavallaro, U., Blagoev, B. & Olsen, J. V. (2013) Functional proteomics defines the molecular switch underlying FGF receptor trafficking and cellular outputs, Mol Cell. 51, 707-22.
7. Hershko, A. & Ciechanover, A. (1998) The ubiquitin system, Annu Rev Biochem. 67, 425-79.
8. Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y. & Mano, H. (2007) Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer, Nature. 448, 561-6.
9. Shaw, A. T. & Engelman, J. A. (2013) ALK in lung cancer: past, present, and future, J Clin Oncol. 31, 1105-11.
10. Hallberg, B. & Palmer, R. H. (2013) Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology, Nat Rev Cancer. 13, 685-700.
11. Shaw, A. T., Kim, D. W., Nakagawa, K., Seto, T., Crino, L., Ahn, M. J., De Pas, T., Besse, B., Solomon, B. J., Blackhall, F., Wu, Y. L., Thomas, M., O'Byrne, K. J., Moro-Sibilot, D., Camidge, D. R., Mok, T., Hirsh, V., Riely, G. J., Iyer, S., Tassell, V., Polli, A., Wilner, K. D. & Janne, P. A. (2013) Crizotinib versus chemotherapy in advanced ALK- positive lung cancer, N Engl J Med. 368, 2385-94.
12. Solomon, B. J., Mok, T., Kim, D. W., Wu, Y. L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., Iyer, S., Reisman, A., Wilner, K. D., Tursi, J., Blackhall, F. & Investigators, P. (2014) First-line crizotinib versus chemotherapy in ALK- positive lung cancer, N Engl J Med. 371, 2167-77.
13. Camidge, D. R., Dziadziuszko, R., Peters, S., Mok, T., Noe, J., Nowicka, M., Gadgeel, S. M., Cheema, P., Pavlakis, N., de Marinis, F., Cho, B. C., Zhang, L., Moro- Sibilot, D., Liu, T., Bordogna, W., Balas, B., Muller, B. & Shaw, A. T. (2019) Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of Alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase III ALEX study, J Thorac Oncol. 14, 1233-43.
14. Nakagawa, K., Hida, T., Nokihara, H., Morise, M., Azuma, K., Kim, Y. H., Seto, T., Takiguchi, Y., Nishio, M., Yoshioka, H., Kumagai, T., Hotta, K., Watanabe, S., Goto, K., Satouchi, M., Kozuki, T., Koyama, R., Mitsudomi, T., Yamamoto, N., Asakawa, T., Hayashi, M., Hasegawa, W. & Tamura, T. (2020) Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer, Lung Cancer. 139, 195-9.
15. Christensen, J. G., Zou, H. Y., Arango, M. E., Li, Q., Lee, J. H., McDonnell, S. R., Yamazaki, S., Alton, G. R., Mroczkowski, B. & Los, G. (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma, Mol Cancer Ther. 6, 3314-22.
16. Sakamoto, H., Tsukaguchi, T., Hiroshima, S., Kodama, T., Kobayashi, T., Fukami, T. A., Oikawa, N., Tsukuda, T., Ishii, N. & Aoki, Y. (2011) CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant, Cancer Cell. 19, 679-90.
17. Popovic, D., Vucic, D. & Dikic, I. (2014) Ubiquitination in disease pathogenesis and treatment, Nat Med. 20, 1242-53.
18. Grabbe, C., Husnjak, K. & Dikic, I. (2011) The spatial and temporal organization of ubiquitin networks, Nat Rev Mol Cell Biol. 12, 295-307.
19. Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., Siegel, D., Orlowski, R. Z., Kuter, D., Limentani, S. A., Lee, S., Hideshima, T., Esseltine, D. L., Kauffman, M., Adams, J., Schenkein, D. P. & Anderson, K. C. (2003) A phase 2 study of bortezomib in relapsed, refractory myeloma, N Engl J Med. 348, 2609-17.
20. Hideshima, T., Richardson, P., Chauhan, D., Palombella, V. J., Elliott, P. J., Adams, J. & Anderson, K. C. (2001) The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells, Cancer Res. 61, 3071-6.
21. Pinho, S. S. & Reis, C. A. (2015) Glycosylation in cancer: mechanisms and clinical implications, Nat Rev Cancer. 15, 540-55.
22. Julien, S., Bobowski, M., Steenackers, A., Le Bourhis, X. & Delannoy, P. (2013) How go gangliosides regulate RTKs signaling?, Cells. 2, 751-67.
23. Sola, R. J. & Griebenow, K. (2009) Effects of glycosylation on the stability of protein pharmaceuticals, J Pharm Sci. 98, 1223-45.
24. Varki, A. (2017) Biological roles of glycans, Glycobiology. 27, 3-49.
25. Schjoldager, K. T., Narimatsu, Y., Joshi, H. J. & Clausen, H. (2020) Global view of human protein glycosylation pathways and functions, Nat Rev Mol Cell Biol. 21, 729-49.
26. Apweiler, R., Hermjakob, H. & Sharon, N. (1999) On the frequency of protein glycosylation, as deduced from analysis of the SWISS-PROT database, Biochim Biophys Acta. 1473, 4-8.
27. Akopian, D., Shen, K., Zhang, X. & Shan, S. O. (2013) Signal recognition particle: an essential protein-targeting machine, Annu Rev Biochem. 82, 693-721.
28. Egea, P. F., Stroud, R. M. & Walter, P. (2005) Targeting proteins to membranes: structure of the signal recognition particle, Curr Opin Struct Biol. 15, 213-20.
29. Song, W., Raden, D., Mandon, E. C. & Gilmore, R. (2000) Role of Sec61alpha in the regulated transfer of the ribosome-nascent chain complex from the signal recognition particle to the translocation channel, Cell. 100, 333-43.
30. Dalbey, R. E., Lively, M. O., Bron, S. & van Dijl, J. M. (1997) The chemistry and enzymology of the type I signal peptidases, Protein Sci. 6, 1129-38.
31. Bolhuis, A., Matzen, A., Hyyrylainen, H. L., Kontinen, V. P., Meima, R., Chapuis, J., Venema, G., Bron, S., Freudl, R. & van Dijl, J. M. (1999) Signal peptide peptidase-and ClpP-like proteins of Bacillus subtilis required for efficient translocation and processing of secretory proteins, J Biol Chem. 274, 24585-92.
32. Reily, C., Stewart, T. J., Renfrow, M. B. & Novak, J. (2019) Glycosylation in health and disease, Nat Rev Nephrol. 15, 346-66.
33. Marshall, R. D. (1972) Glycoproteins, Annu Rev Biochem. 41, 673-702.
34. Spiro, R. G. (2002) Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds, Glycobiology. 12, 43R-56R.
35. Aebi, M. (2013) N-linked protein glycosylation in the ER, Biochim Biophys Acta. 1833, 2430-7.
36. Breitling, J. & Aebi, M. (2013) N-linked protein glycosylation in the endoplasmic reticulum, Cold Spring Harb Perspect Biol. 5, a013359.
37. Kim, D. S., Choi, D. & Hahn, Y. (2015) Loss of ancestral N-glycosylation sites in conserved proteins during human evolution, Int J Mol Med. 36, 1685-92.
38. Tannous, A., Pisoni, G. B., Hebert, D. N. & Molinari, M. (2015) N-linked sugar- regulated protein folding and quality control in the ER, Semin Cell Dev Biol. 41, 79-89.
39. Heifetz, A., Keenan, R. W. & Elbein, A. D. (1979) Mechanism of action of tunicamycin on the UDP-GlcNAc:dolichyl-phosphate Glc-NAc-1-phosphate transferase, Biochemistry. 18, 2186-92.
40. Li, C. W., Lim, S. O., Xia, W., Lee, H. H., Chan, L. C., Kuo, C. W., Khoo, K. H., Chang, S. S., Cha, J. H., Kim, T., Hsu, J. L., Wu, Y., Hsu, J. M., Yamaguchi, H., Ding, Q., Wang, Y., Yao, J., Lee, C. C., Wu, H. J., Sahin, A. A., Allison, J. P., Yu, D., Hortobagyi, G. N. & Hung, M. C. (2016) Glycosylation and stabilization of programmed death ligand- 1 suppresses T-cell activity, Nat Commun. 7, 12632.
41. Benicky, J., Sanda, M., Brnakova Kennedy, Z., Grant, O. C., Woods, R. J., Zwart, A. & Goldman, R. (2021) PD-L1 glycosylation and its impact on binding to clinical antibodies, J Proteome Res. 20, 485-97.
42. Liu, K., Tan, S., Jin, W., Guan, J., Wang, Q., Sun, H., Qi, J., Yan, J., Chai, Y., Wang, Z., Deng, C. & Gao, G. F. (2020) N-glycosylation of PD-1 promotes binding of camrelizumab, EMBO Rep. 21, e51444.
43. Li, S. M., Zhou, J., Wang, Y., Nie, R. C., Chen, J. W. & Xie, D. (2020) Recent findings in the posttranslational modifications of PD-L1, J Oncol. 2020, 5497015.
44. Wu, Y. M., Liu, C. H., Hu, R. H., Huang, M. J., Lee, J. J., Chen, C. H., Huang, J., Lai, H. S., Lee, P. H., Hsu, W. M., Huang, H. C. & Huang, M. C. (2011) Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor, Cancer Res. 71, 7270-9.
45. Wang, Z. Q., Bachvarova, M., Morin, C., Plante, M., Gregoire, J., Renaud, M. C., Sebastianelli, A. & Bachvarov, D. (2014) Role of the polypeptide N- acetylgalactosaminyltransferase 3 in ovarian cancer progression: possible implications in abnormal mucin O-glycosylation, Oncotarget. 5, 544-60.
46. Kinoshita, T. (2020) Biosynthesis and biology of mammalian GPI-anchored proteins, Open Biol. 10, 190290.
47. Homans, S. W., Ferguson, M. A., Dwek, R. A., Rademacher, T. W., Anand, R. & Williams, A. F. (1988) Complete structure of the glycosyl phosphatidylinositol membrane anchor of rat brain Thy-1 glycoprotein, Nature. 333, 269-72.
48. Altevogt, P., Sammar, M., Huser, L. & Kristiansen, G. (2021) Novel insights into the function of CD24: A driving force in cancer, Int J Cancer. 148, 546-59.
49. Barkal, A. A., Brewer, R. E., Markovic, M., Kowarsky, M., Barkal, S. A., Zaro, B. W., Krishnan, V., Hatakeyama, J., Dorigo, O., Barkal, L. J. & Weissman, I. L. (2019) CD24 signalling through macrophage Siglec-10 is a target for cancer immunotherapy, Nature. 572, 392-6.
50. Hofsteenge, J., Muller, D. R., de Beer, T., Loffler, A., Richter, W. J. & Vliegenthart, J. F. (1994) New type of linkage between a carbohydrate and a protein: C-glycosylation of a specific tryptophan residue in human RNase Us, Biochemistry. 33, 13524-30.
51. de Beer, T., Vliegenthart, J. F., Loffler, A. & Hofsteenge, J. (1995) The hexopyranosyl residue that is C-glycosidically linked to the side chain of tryptophan-7 in human RNase Us is α-mannopyranose, Biochemistry. 34, 11785-9.
52. Loffler, A., Doucey, M. A., Jansson, A. M., Muller, D. R., de Beer, T., Hess, D., Meldal, M., Richter, W. J., Vliegenthart, J. F. & Hofsteenge, J. (1996) Spectroscopic and protein chemical analyses demonstrate the presence of C-mannosylated tryptophan in intact human RNase 2 and its isoforms, Biochemistry. 35, 12005-14.
53. Frank, M., Beccati, D., Leeflang, B. R. & Vliegenthart, J. F. G. (2020) C- mannosylation enhances the structural stability of human RNase 2, iScience. 23, 101371.
54. Krieg, J., Hartmann, S., Vicentini, A., Glasner, W., Hess, D. & Hofsteenge, J. (1998) Recognition signal for C-mannosylation of Trp-7 in RNase 2 consists of sequence Trp-x- x-Trp, Mol Biol Cell. 9, 301-9.
55. Julenius, K. (2007) NetCGlyc 1.0: prediction of mammalian C-mannosylation sites, Glycobiology. 17, 868-76.
56. Hofsteenge, J., Blommers, M., Hess, D., Furmanek, A. & Miroshnichenko, O. (1999) The four terminal components of the complement system are C-mannosylated on multiple tryptophan residues, J Biol Chem. 274, 32786-94.
57. Miura, K., Suzuki, T., Sun, H., Takada, H., Ishizawa, Y., Mizuta, H., Dohmae, N. & Simizu, S. (2021) Requirement for C-mannosylation to be secreted and activated a disintegrin and metalloproteinase with thrombospondin motifs 4 (ADAMTS4), Biochim Biophys Acta Gen Subj. 1865, 129833.
58. Doucey, M. A., Hess, D., Cacan, R. & Hofsteenge, J. (1998) Protein C- mannosylation is enzyme-catalysed and uses dolichyl-phosphate-mannose as a precursor, Mol Biol Cell. 9, 291-300.
59. Buettner, F. F., Ashikov, A., Tiemann, B., Lehle, L. & Bakker, H. (2013) C. elegans DPY-19 is a C-mannosyltransferase glycosylating thrombospondin repeats, Mol Cell. 50, 295-302.
60. Niwa, Y., Suzuki, T., Dohmae, N. & Simizu, S. (2016) Identification of DPY19L3 as the C-mannosyltransferase of R-spondin1 in human cells, Mol Biol Cell. 27, 744-56.
61. Shcherbakova, A., Tiemann, B., Buettner, F. F. & Bakker, H. (2017) Distinct C- mannosylation of netrin receptor thrombospondin type 1 repeats by mammalian DPY19L1 and DPY19L3, Proc Natl Acad Sci U S A. 114, 2574-9.
62. Otani, K., Niwa, Y., Suzuki, T., Sato, N., Sasazawa, Y., Dohmae, N. & Simizu, S. (2018) Regulation of granulocyte colony-stimulating factor receptor-mediated granulocytic differentiation by C-mannosylation, Biochem Biophys Res Commun. 498, 466-72.
63. Sasazawa, Y., Sato, N., Suzuki, T., Dohmae, N. & Simizu, S. (2015) C- mannosylation of thrombopoietin receptor (c-Mpl) regulates thrombopoietin-dependent JAK-STAT signaling, Biochem Biophys Res Commun. 468, 262-8.
64. Nishitsuji, K., Ikezaki, M., Manabe, S., Uchimura, K., Ito, Y. & Ihara, Y. (2021) Thrombospondin type 1 repeat-derived C-mannosylated peptide attenuates synaptogenesis of cortical neurons induced by primary astrocytes via TGF-β, Glycoconj J. Online ahead of print.
65. Ikezaki, M., Nishitsuji, K., Matsumura, K., Manabe, S., Shibukawa, Y., Wada, Y., Ito, Y. & Ihara, Y. (2022) C-Mannosylated tryptophan-containing WSPW peptide binds to actinin-4 and alters E-cadherin subcellular localization in lung epithelial-like A549 cells, Biochimie. 192, 136-46.
66. Hendee, K., Wang, L. W., Reis, L. M., Rice, G. M., Apte, S. S. & Semina, E. V. (2017) Identification and functional analysis of an ADAMTSL1 variant associated with a complex phenotype including congenital glaucoma, craniofacial, and other systemic features in a three-generation human pedigree, Hum Mutat. 38, 1485-90.
67. Kazanskaya, O., Glinka, A., del Barco Barrantes, I., Stannek, P., Niehrs, C. & Wu, W. (2004) R-Spondin2 is a secreted activator of Wnt/β-catenin signaling and is required for Xenopus myogenesis, Dev Cell. 7, 525-34.
68. Hao, H. X., Jiang, X. & Cong, F. (2016) Control of wnt receptor turnover by R- spondin-ZNRF3/RNF43 signaling module and its dysregulation in cancer, Cancers (Basel). 8, 54.
69. Willert, K., Brown, J. D., Danenberg, E., Duncan, A. W., Weissman, I. L., Reya, T., Yates, J. R., 3rd & Nusse, R. (2003) Wnt proteins are lipid-modified and can act as stem cell growth factors, Nature. 423, 448-52.
70. Liu, C., Li, Y., Semenov, M., Han, C., Baeg, G. H., Tan, Y., Zhang, Z., Lin, X. & He, X. (2002) Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism, Cell. 108, 837-47.
71. Aberle, H., Bauer, A., Stappert, J., Kispert, A. & Kemler, R. (1997) β-catenin is a target for the ubiquitin-proteasome pathway, EMBO J. 16, 3797-804.
72. Kitagawa, M., Hatakeyama, S., Shirane, M., Matsumoto, M., Ishida, N., Hattori, K., Nakamichi, I., Kikuchi, A., Nakayama, K. & Nakayama, K. (1999) An F-box protein, FWD1, mediates ubiquitin-dependent proteolysis of β-catenin, EMBO J. 18, 2401-10.
73. Cavallo, R. A., Cox, R. T., Moline, M. M., Roose, J., Polevoy, G. A., Clevers, H., Peifer, M. & Bejsovec, A. (1998) Drosophila Tcf and Groucho interact to repress Wingless signalling activity, Nature. 395, 604-8.
74. Janda, C. Y., Dang, L. T., You, C., Chang, J., de Lau, W., Zhong, Z. A., Yan, K. S., Marecic, O., Siepe, D., Li, X., Moody, J. D., Williams, B. O., Clevers, H., Piehler, J., Baker, D., Kuo, C. J. & Garcia, K. C. (2017) Surrogate Wnt agonists that phenocopy canonical Wnt and β-catenin signalling, Nature. 545, 234-7.
75. Stamos, J. L., Chu, M. L., Enos, M. D., Shah, N. & Weis, W. I. (2014) Structural basis of GSK-3 inhibition by N-terminal phosphorylation and by the Wnt receptor LRP6, Elife. 3, e01998.
76. Tauriello, D. V., Jordens, I., Kirchner, K., Slootstra, J. W., Kruitwagen, T., Bouwman, B. A., Noutsou, M., Rudiger, S. G., Schwamborn, K., Schambony, A. & Maurice, M. M. (2012) Wnt/β-catenin signaling requires interaction of the Dishevelled DEP domain and C terminus with a discontinuous motif in Frizzled, Proc Natl Acad Sci U S A. 109, E812- 20.
77. Schwarz-Romond, T., Fiedler, M., Shibata, N., Butler, P. J., Kikuchi, A., Higuchi, Y. & Bienz, M. (2007) The DIX domain of Dishevelled confers Wnt signaling by dynamic polymerization, Nat Struct Mol Biol. 14, 484-92.
78. Fiedler, M., Mendoza-Topaz, C., Rutherford, T. J., Mieszczanek, J. & Bienz, M. (2011) Dishevelled interacts with the DIX domain polymerization interface of Axin to interfere with its function in down-regulating β-catenin, Proc Natl Acad Sci U S A. 108, 1937-42.
79. Kim, S. E., Huang, H., Zhao, M., Zhang, X., Zhang, A., Semonov, M. V., MacDonald, B. T., Zhang, X., Garcia Abreu, J., Peng, L. & He, X. (2013) Wnt stabilization of β-catenin reveals principles for morphogen receptor-scaffold assemblies, Science. 340, 867-70.
80. Behrens, J., von Kries, J. P., Kuhl, M., Bruhn, L., Wedlich, D., Grosschedl, R. & Birchmeier, W. (1996) Functional interaction of β-catenin with the transcription factor LEF-1, Nature. 382, 638-42.
81. Molenaar, M., van de Wetering, M., Oosterwegel, M., Peterson-Maduro, J., Godsave, S., Korinek, V., Roose, J., Destree, O. & Clevers, H. (1996) XTcf-3 transcription factor mediates β-catenin-induced axis formation in Xenopus embryos, Cell. 86, 391-9.
82. He, T. C., Sparks, A. B., Rago, C., Hermeking, H., Zawel, L., da Costa, L. T., Morin, P. J., Vogelstein, B. & Kinzler, K. W. (1998) Identification of c-MYC as a target of the APC pathway, Science. 281, 1509-12.
83. Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D'Amico, M., Pestell, R. & Ben-Ze'ev, A. (1999) The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway, Proc Natl Acad Sci U S A. 96, 5522-7.
84. Hao, H. X., Xie, Y., Zhang, Y., Charlat, O., Oster, E., Avello, M., Lei, H., Mickanin, C., Liu, D., Ruffner, H., Mao, X., Ma, Q., Zamponi, R., Bouwmeester, T., Finan, P. M., Kirschner, M. W., Porter, J. A., Serluca, F. C. & Cong, F. (2012) ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner, Nature. 485, 195-200.
85. Koo, B. K., Spit, M., Jordens, I., Low, T. Y., Stange, D. E., van de Wetering, M., van Es, J. H., Mohammed, S., Heck, A. J., Maurice, M. M. & Clevers, H. (2012) Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors, Nature. 488, 665-9.
86. Glinka, A., Dolde, C., Kirsch, N., Huang, Y. L., Kazanskaya, O., Ingelfinger, D., Boutros, M., Cruciat, C. M. & Niehrs, C. (2011) LGR4 and LGR5 are R-spondin receptors mediating Wnt/β-catenin and Wnt/PCP signalling, EMBO Rep. 12, 1055-61.
87. Carmon, K. S., Gong, X., Lin, Q., Thomas, A. & Liu, Q. (2011) R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/β-catenin signaling, Proc Natl Acad Sci U S A. 108, 11452-7.
88. de Lau, W., Barker, N., Low, T. Y., Koo, B. K., Li, V. S., Teunissen, H., Kujala, P., Haegebarth, A., Peters, P. J., van de Wetering, M., Stange, D. E., van Es, J. E., Guardavaccaro, D., Schasfoort, R. B., Mohri, Y., Nishimori, K., Mohammed, S., Heck, A. J. & Clevers, H. (2011) Lgr5 homologues associate with Wnt receptors and mediate R- spondin signalling, Nature. 476, 293-7.
89. Ruffner, H., Sprunger, J., Charlat, O., Leighton-Davies, J., Grosshans, B., Salathe, A., Zietzling, S., Beck, V., Therier, M., Isken, A., Xie, Y., Zhang, Y., Hao, H., Shi, X., Liu, D., Song, Q., Clay, I., Hintzen, G., Tchorz, J., Bouchez, L. C., Michaud, G., Finan, P., Myer, V. E., Bouwmeester, T., Porter, J., Hild, M., Bassilana, F., Parker, C. N. & Cong, F. (2012) R-Spondin potentiates Wnt/β-catenin signaling through orphan receptors LGR4 and LGR5, PLoS One. 7, e40976.
90. Zebisch, M., Xu, Y., Krastev, C., MacDonald, B. T., Chen, M., Gilbert, R. J., He, X. & Jones, E. Y. (2013) Structural and molecular basis of ZNRF3/RNF43 transmembrane ubiquitin ligase inhibition by the Wnt agonist R-spondin, Nat Commun. 4, 2787.
91. Moad, H. E. & Pioszak, A. A. (2013) Reconstitution of R-spondin:LGR4:ZNRF3 adult stem cell growth factor signaling complexes with recombinant proteins produced in Escherichia coli, Biochemistry. 52, 7295-304.
92. Chen, P. H., Chen, X., Lin, Z., Fang, D. & He, X. (2013) The structural basis of R- spondin recognition by LGR5 and RNF43, Genes Dev. 27, 1345-50.
93. Szenker-Ravi, E., Altunoglu, U., Leushacke, M., Bosso-Lefevre, C., Khatoo, M., Thi Tran, H., Naert, T., Noelanders, R., Hajamohideen, A., Beneteau, C., de Sousa, S. B., Karaman, B., Latypova, X., Basaran, S., Yucel, E. B., Tan, T. T., Vlaminck, L., Nayak, S. S., Shukla, A., Girisha, K. M., Le Caignec, C., Soshnikova, N., Uyguner, Z. O., Vleminckx, K., Barker, N., Kayserili, H. & Reversade, B. (2018) RSPO2 inhibition of RNF43 and ZNRF3 governs limb development independently of LGR4/5/6, Nature. 557, 564-9.
94. MacDonald, B. T., Tamai, K. & He, X. (2009) Wnt/β-catenin signaling: components, mechanisms, and diseases, Dev Cell. 17, 9-26.
95. Nam, J. S., Park, E., Turcotte, T. J., Palencia, S., Zhan, X., Lee, J., Yun, K., Funk, W. D. & Yoon, J. K. (2007) Mouse R-spondin2 is required for apical ectodermal ridge maintenance in the hindlimb, Dev Biol. 311, 124-35.
96. Aoki, M., Kiyonari, H., Nakamura, H. & Okamoto, H. (2008) R-spondin2 expression in the apical ectodermal ridge is essential for outgrowth and patterning in mouse limb development, Dev Growth Differ. 50, 85-95.
97. Bell, S. M., Schreiner, C. M., Wert, S. E., Mucenski, M. L., Scott, W. J. & Whitsett, J. A. (2008) R-spondin 2 is required for normal laryngeal-tracheal, lung and limb morphogenesis, Development. 135, 1049-58.
98. Ilmer, M., Boiles, A. R., Regel, I., Yokoi, K., Michalski, C. W., Wistuba, II, Rodriguez, J., Alt, E. & Vykoukal, J. (2015) RSPO2 enhances canonical Wnt signaling to confer stemness-associated traits to susceptible pancreatic cancer cells, Cancer Res. 75, 1883-96.
99. Michelotti, G., Jiang, X., Sosa, J. A., Diehl, A. M. & Henderson, B. B. (2015) LGR5 is associated with tumor aggressiveness in papillary thyroid cancer, Oncotarget. 6, 34549- 60.
100. Zhang, H., Han, X., Wei, B., Fang, J., Hou, X., Lan, T. & Wei, H. (2019) RSPO2 enhances cell invasion and migration via the Wnt/β-catenin pathway in human gastric cancer, J Cell Biochem. 120, 5813-24.
101. Yoon, J. K. & Lee, J. S. (2012) Cellular signaling and biological functions of R- spondins, Cell Signal. 24, 369-77.
102. de Lau, W. B., Snel, B. & Clevers, H. C. (2012) The R-spondin protein family, Genome Biol. 13, 242.
103. Fujiwara, M., Kato, S., Niwa, Y., Suzuki, T., Tsuchiya, M., Sasazawa, Y., Dohmae, N. & Simizu, S. (2016) C-mannosylation of R-spondin3 regulates its secretion and activity of Wnt/β-catenin signaling in cells, FEBS Lett. 590, 2639-49.
104. McLatchie, L. M., Fraser, N. J., Main, M. J., Wise, A., Brown, J., Thompson, N., Solari, R., Lee, M. G. & Foord, S. M. (1998) RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor, Nature. 393, 333-9.
105. Pioszak, A. A. & Hay, D. L. (2020) RAMPs as allosteric modulators of the calcitonin and calcitonin-like class B G protein-coupled receptors, Adv Pharmacol. 88, 115-41.
106. Hoare, S. R. (2005) Mechanisms of peptide and nonpeptide ligand binding to Class B G-protein-coupled receptors, Drug Discov Today. 10, 417-27.
107. Naot, D., Musson, D. S. & Cornish, J. (2019) The activity of peptides of the calcitonin family in bone, Physiol Rev. 99, 781-805.
108. Hay, D. L., Chen, S., Lutz, T. A., Parkes, D. G. & Roth, J. D. (2015) Amylin: pharmacology, physiology, and clinical potential, Pharmacol Rev. 67, 564-600.
109. Kee, Z., Kodji, X. & Brain, S. D. (2018) The role of calcitonin gene related peptide (CGRP) in neurogenic vasodilation and its cardioprotective effects, Front Physiol. 9, 1249.
110. Russell, F. A., King, R., Smillie, S. J., Kodji, X. & Brain, S. D. (2014) Calcitonin gene-related peptide: physiology and pathophysiology, Physiol Rev. 94, 1099-142.
111. Edvinsson, L., Haanes, K. A., Warfvinge, K. & Krause, D. N. (2018) CGRP as the target of new migraine therapies - successful translation from bench to clinic, Nat Rev Neurol. 14, 338-50.
112. Kato, J. & Kitamura, K. (2015) Bench-to-bedside pharmacology of adrenomedullin, Eur J Pharmacol. 764, 140-8.
113. Klein, K. R. & Caron, K. M. (2015) Adrenomedullin in lymphangiogenesis: from development to disease, Cell Mol Life Sci. 72, 3115-26.
114. Lenhart, P. M. & Caron, K. M. (2012) Adrenomedullin and pregnancy: perspectives from animal models to humans, Trends Endocrinol Metab. 23, 524-32.
115. Tsuruda, T., Kato, J., Kuwasako, K. & Kitamura, K. (2019) Adrenomedullin: Continuing to explore cardioprotection, Peptides. 111, 47-54.
116. Zhang, S. Y., Xu, M. J. & Wang, X. (2018) Adrenomedullin 2/intermedin: a putative drug candidate for treatment of cardiometabolic diseases, Br J Pharmacol. 175, 1230-40.
117. Hay, D. L., Garelja, M. L., Poyner, D. R. & Walker, C. S. (2018) Update on the pharmacology of calcitonin/CGRP family of peptides: IUPHAR Review 25, Br J Pharmacol. 175, 3-17.
118. Hong, Y., Hay, D. L., Quirion, R. & Poyner, D. R. (2012) The pharmacology of adrenomedullin 2/intermedin, Br J Pharmacol. 166, 110-20.
119. Poyner, D. R., Sexton, P. M., Marshall, I., Smith, D. M., Quirion, R., Born, W., Muff, R., Fischer, J. A. & Foord, S. M. (2002) International union of pharmacology. XXXII. The mammalian calcitonin gene-related peptides, adrenomedullin, amylin, and calcitonin receptors, Pharmacol Rev. 54, 233-46.
120. Chiba, T., Yamaguchi, A., Yamatani, T., Nakamura, A., Morishita, T., Inui, T., Fukase, M., Noda, T. & Fujita, T. (1989) Calcitonin gene-related peptide receptor antagonist human CGRP-(8-37), Am J Physiol. 256, E331-5.
121. Hasbak, P., Eskesen, K., Schifter, S. & Edvinsson, L. (2005) Increased αCGRP potency and CGRP-receptor antagonist affinity in isolated hypoxic porcine intramyocardial arteries, Br J Pharmacol. 145, 646-55.
122. Zhang, L., Bonev, A. D., Mawe, G. M. & Nelson, M. T. (1994) Protein kinase A mediates activation of ATP-sensitive K+ currents by CGRP in gallbladder smooth muscle, Am J Physiol. 267, G494-9.
123. Wang, Z., Ma, W., Chabot, J. G. & Quirion, R. (2009) Cell-type specific activation of p38 and ERK mediates calcitonin gene-related peptide involvement in tolerance to morphine-induced analgesia, FASEB J. 23, 2576-86.
124. Yu, X. J., Li, C. Y., Wang, K. Y. & Dai, H. Y. (2006) Calcitonin gene-related peptide regulates the expression of vascular endothelial growth factor in human HaCaT keratinocytes by activation of ERK1/2 MAPK, Regul Pept. 137, 134-9.
125. Evans, B. N., Rosenblatt, M. I., Mnayer, L. O., Oliver, K. R. & Dickerson, I. M. (2000) CGRP-RCP, a novel protein required for signal transduction at calcitonin gene- related peptide and adrenomedullin receptors, J Biol Chem. 275, 31438-43.
126. Morara, S., Wang, L. P., Filippov, V., Dickerson, I. M., Grohovaz, F., Provini, L. & Kettenmann, H. (2008) Calcitonin gene-related peptide (CGRP) triggers Ca2+ responses in cultured astrocytes and in Bergmann glial cells from cerebellar slices, Eur J Neurosci. 28, 2213-20.
127. Drissi, H., Lieberherr, M., Hott, M., Marie, P. J. & Lasmoles, F. (1999) Calcitonin gene-related peptide (CGRP) increases intracellular free Ca2+ concentrations but not cyclic AMP formation in CGRP receptor-positive osteosarcoma cells (OHS-4), Cytokine. 11, 200-7.
128. Ritter, S. L. & Hall, R. A. (2009) Fine-tuning of GPCR activity by receptor- interacting proteins, Nat Rev Mol Cell Biol. 10, 819-30.
129. Defea, K. (2008) β-arrestins and heterotrimeric G-proteins: collaborators and competitors in signal transduction, Br J Pharmacol. 153 Suppl 1, S298-309.
130. Wiley, J. W., Gross, R. A. & MacDonald, R. L. (1992) The peptide CGRP increases a high-threshold Ca2+ current in rat nodose neurones via a pertussis toxin-sensitive pathway, J Physiol. 455, 367-81.
131. Walker, C. S., Conner, A. C., Poyner, D. R. & Hay, D. L. (2010) Regulation of signal transduction by calcitonin gene-related peptide receptors, Trends Pharmacol Sci. 31, 476-83.
132. Dallmayer, M., Li, J., Ohmura, S., Alba Rubio, R., Baldauf, M. C., Holting, T. L. B., Musa, J., Knott, M. M. L., Stein, S., Cidre-Aranaz, F., Wehweck, F. S., Romero-Perez, L., Gerke, J. S., Orth, M. F., Marchetto, A., Kirchner, T., Bach, H., Sannino, G. & Grunewald, T. G. P. (2019) Targeting the CALCB/RAMP1 axis inhibits growth of Ewing sarcoma, Cell Death Dis. 10, 116.
133. Logan, M., Anderson, P. D., Saab, S. T., Hameed, O. & Abdulkadir, S. A. (2013) RAMP1 is a direct NKX3.1 target gene up-regulated in prostate cancer that promotes tumorigenesis, Am J Pathol. 183, 951-63.
134. Gluexam, T., Grandits, A. M., Schlerka, A., Nguyen, C. H., Etzler, J., Finkes, T., Fuchs, M., Scheid, C., Heller, G., Hackl, H., Harrer, N., Sill, H., Koller, E., Stoiber, D., Sommergruber, W. & Wieser, R. (2019) CGRP signaling via CALCRL increases chemotherapy resistance and stem cell properties in acute myeloid leukemia, Int J Mol Sci. 20, 5826.
135. Aryal, B., Price, N. L., Suarez, Y. & Fernandez-Hernando, C. (2019) ANGPTL4 in metabolic and cardiovascular disease, Trends Mol Med. 25, 723-34.
136. Zhu, P., Goh, Y. Y., Chin, H. F., Kersten, S. & Tan, N. S. (2012) Angiopoietin-like 4: a decade of research, Biosci Rep. 32, 211-9.
137. Koishi, R., Ando, Y., Ono, M., Shimamura, M., Yasumo, H., Fujiwara, T., Horikoshi, H. & Furukawa, H. (2002) Angptl3 regulates lipid metabolism in mice, Nat Genet. 30, 151-7.
138. Shimizugawa, T., Ono, M., Shimamura, M., Yoshida, K., Ando, Y., Koishi, R., Ueda, K., Inaba, T., Minekura, H., Kohama, T. & Furukawa, H. (2002) ANGPTL3 decreases very low density lipoprotein triglyceride clearance by inhibition of lipoprotein lipase, J Biol Chem. 277, 33742-8.
139. Sukonina, V., Lookene, A., Olivecrona, T. & Olivecrona, G. (2006) Angiopoietin- like protein 4 converts lipoprotein lipase to inactive monomers and modulates lipase activity in adipose tissue, Proc Natl Acad Sci U S A. 103, 17450-5.
140. Zhang, R. (2016) The ANGPTL3-4-8 model, a molecular mechanism for triglyceride trafficking, Open Biol. 6, 150272.
141. Dijk, W. & Kersten, S. (2016) Regulation of lipid metabolism by angiopoietin-like proteins, Curr Opin Lipidol. 27, 249-56.
142. Hato, T., Tabata, M. & Oike, Y. (2008) The role of angiopoietin-like proteins in angiogenesis and metabolism, Trends Cardiovasc Med. 18, 6-14.
143. Santulli, G. (2014) Angiopoietin-like proteins: a comprehensive look, Front Endocrinol (Lausanne). 5, 4.
144. Fernandez-Hernando, C. & Suarez, Y. (2020) ANGPTL4: a multifunctional protein involved in metabolism and vascular homeostasis, Curr Opin Hematol. 27, 206-13.
145. Kim, S. H., Park, Y. Y., Kim, S. W., Lee, J. S., Wang, D. & DuBois, R. N. (2011) ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression, Cancer Res. 71, 7010-20.
146. Tanaka, J., Irie, T., Yamamoto, G., Yasuhara, R., Isobe, T., Hokazono, C., Tachikawa, T., Kohno, Y. & Mishima, K. (2015) ANGPTL4 regulates the metastatic potential of oral squamous cell carcinoma, J Oral Pathol Med. 44, 126-33.
147. Zhao, J., Liu, J., Wu, N., Zhang, H., Zhang, S., Li, L. & Wang, M. (2020) ANGPTL4 overexpression is associated with progression and poor prognosis in breast cancer, Oncol Lett. 20, 2499-505.
148. Zhu, X., Guo, X., Wu, S. & Wei, L. (2016) ANGPTL4 correlates with NSCLC progression and regulates epithelial-mesenchymal transition via ERK pathway, Lung. 194, 637-46.
149. Chang, C. F., Hsu, L. S., Weng, C. Y., Chen, C. K., Wang, S. Y., Chou, Y. H., Liu, Y. Y., Yuan, Z. X., Huang, W. Y., Lin, H., Chen, Y. H. & Tsai, J. N. (2016) N-Glycosylation of human R-spondin 1 is required for efficient secretion and stability but not for its heparin binding ability, Int J Mol Sci. 17, 937
150. Sorvillo, N., Kaijen, P. H., Matsumoto, M., Fujimura, Y., van der Zwaan, C., Verbij, F. C., Pos, W., Fijnheer, R., Voorberg, J. & Meijer, A. B. (2014) Identification of N-linked glycosylation and putative O-fucosylation, C-mannosylation sites in plasma derived ADAMTS13, J Thromb Haemost. 12, 670-9.
151. Li, J. S., Cui, L., Rock, D. L. & Li, J. (2005) Novel glycosidic linkage in Aedes aegypti chorion peroxidase: N-mannosyl tryptophan, J Biol Chem. 280, 38513-21.
152. Brunner, F., Wirtz, W., Rose, J. K., Darvill, A. G., Govers, F., Scheel, D. & Nurnberger, T. (2002) A β-glucosidase/xylosidase from the phytopathogenic oomycete, Phytophthora infestans, Phytochemistry. 59, 689-96.
153. Yin, X., Yi, H., Wang, L., Wu, W., Wu, X. & Yu, L. (2017) R-spondin 2 promotes proliferation and migration via the Wnt/β-catenin pathway in human hepatocellular carcinoma, Oncol Lett. 14, 1757-65.
154. Dong, X., Liao, W., Zhang, L., Tu, X., Hu, J., Chen, T., Dai, X., Xiong, Y., Liang, W., Ding, C., Liu, R., Dai, J., Wang, O., Lu, L. & Lu, X. (2017) RSPO2 suppresses colorectal cancer metastasis by counteracting the Wnt5a/Fzd7-driven noncanonical Wnt pathway, Cancer Lett. 402, 153-65.
155. Diem, S., Bergmann, J. & Herderich, M. (2000) Tryptophan-N-glucoside in fruits and fruit juices, J Agric Food Chem. 48, 4913-7.
156. Rabouille, C. (2017) Pathways of unconventional protein secretion, Trends Cell Biol. 27, 230-40.
157. Grieve, A. G. & Rabouille, C. (2011) Golgi bypass: skirting around the heart of classical secretion, Cold Spring Harb Perspect Biol. 3, a005298.
158. Shcherbakova, A., Preller, M., Taft, M. H., Pujols, J., Ventura, S., Tiemann, B., Buettner, F. F. & Bakker, H. (2019) C-mannosylation supports folding and enhances stability of thrombospondin repeats, Elife. 8, e52978.
159. Pedersen, D. V., Gadeberg, T. A. F., Thomas, C., Wang, Y., Joram, N., Jensen, R. K., Mazarakis, S. M. M., Revel, M., El Sissy, C., Petersen, S. V., Lindorff-Larsen, K., Thiel, S., Laursen, N. S., Fremeaux-Bacchi, V. & Andersen, G. R. (2019) Structural basis for Properdin oligomerization and convertase stimulation in the human complement system, Front Immunol. 10, 2007.
160. van den Bos, R. M., Pearce, N. M., Granneman, J., Brondijk, T. H. C. & Gros, P. (2019) Insights into enhanced complement activation by structures of Properdin and its complex with the C-terminal domain of C3b, Front Immunol. 10, 2097.
161. Krieg, J., Glasner, W., Vicentini, A., Doucey, M. A., Loffler, A., Hess, D. & Hofsteenge, J. (1997) C-Mannosylation of human RNase 2 is an intracellular process performed by a variety of cultured cells, J Biol Chem. 272, 26687-92.
162. Hofsteenge, J., Huwiler, K. G., Macek, B., Hess, D., Lawler, J., Mosher, D. F. & Peter-Katalinic, J. (2001) C-mannosylation and O-fucosylation of the thrombospondin type 1 module, J Biol Chem. 276, 6485-98.
163. Zhang, Q., Guo, Y., Chen, H., Jiang, Y., Tang, H., Gong, P. & Xiang, L. (2019) The influence of receptor activity-modifying protein-1 overexpression on angiogenesis in mouse brain capillary endothelial cells, J Cell Biochem. 120, 10087-96.
164. Liu, Y., Zhang, S., Xue, J., Wei, Z., Ao, P., Shen, B. & Ding, L. (2019) CGRP reduces apoptosis of DRG cells induced by high-glucose oxidative stress injury through PI3K/AKT induction of Heme oxygenase-1 and Nrf-2 expression, Oxid Med Cell Longev. 2019, 2053149.
165. Morishita, S., Suzuki, T., Niwa, Y., Dohmae, N. & Simizu, S. (2017) Dpy-19 like 3-mediated C-mannosylation and expression levels of RPE-spondin in human tumor cell lines, Oncol Lett. 14, 2537-44.
166. Tan, K., Duquette, M., Liu, J. H., Dong, Y., Zhang, R., Joachimiak, A., Lawler, J. & Wang, J. H. (2002) Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication, J Cell Biol. 159, 373-82.
167. Kusano, S., Kukimoto-Niino, M., Akasaka, R., Toyama, M., Terada, T., Shirouzu, M., Shindo, T. & Yokoyama, S. (2008) Crystal structure of the human receptor activity- modifying protein 1 extracellular domain, Protein Sci. 17, 1907-14.
168. Archbold, J. K., Flanagan, J. U., Watkins, H. A., Gingell, J. J. & Hay, D. L. (2011) Structural insights into RAMP modification of secretin family G protein-coupled receptors: implications for drug development, Trends Pharmacol Sci. 32, 591-600.
169. Moore, E. L., Gingell, J. J., Kane, S. A., Hay, D. L. & Salvatore, C. A. (2010) Mapping the CGRP receptor ligand binding domain: tryptophan-84 of RAMP1 is critical for agonist and antagonist binding, Biochem Biophys Res Commun. 394, 141-5.
170. Mori, K., Suzuki, T., Miura, K., Dohmae, N. & Simizu, S. (2021) Involvement of LH3 and GLT25D1 for glucosyl-galactosyl-hydroxylation on non-collagen-like domain of FGL1, Biochem Biophys Res Commun. 560, 93-8.
171. Osada, Y., Suzuki, T., Mizuta, H., Mori, K., Miura, K., Dohmae, N. & Simizu, S. (2020) The fibrinogen C-terminal domain is seldom C-mannosylated but its C- mannosylation is important for the secretion of microfibril-associated glycoprotein 4, Biochim Biophys Acta Gen Subj. 1864, 129637.
172. Luo, G., Jin, K., Deng, S., Cheng, H., Fan, Z., Gong, Y., Qian, Y., Huang, Q., Ni, Q., Liu, C. & Yu, X. (2021) Roles of CA19-9 in pancreatic cancer: Biomarker, predictor and promoter, Biochim Biophys Acta Rev Cancer. 1875, 188409.
論文の公開元へ
